おすすめの製品
グレード
pharmaceutical primary standard
APIファミリー
quinidine
メーカー／製品名
EDQM
mp
212-214 °C (dec.) (lit.)
アプリケーション
pharmaceutical (small molecule)
フォーマット
neat
保管温度
2-8°C
SMILES記法
[H]O[H].[H]O[H].OS(O)(=O)=O.[H][C@]1(CN2CCC1C[C@]2([H])[C@@H](O)c3ccnc4ccc(OC)cc34)C=C.[H][C@]5(CN6CCC5C[C@]6([H])[C@@H](O)c7ccnc8ccc(OC)cc78)C=C
InChI
1S/2C20H24N2O2.H2O4S.2H2O/c2*1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;1-5(2,3)4;;/h2*3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;(H2,1,2,3,4);2*1H2/t2*13-,14?,19-,20+;;;/m11.../s1
InChI Key
ZHNFLHYOFXQIOW-WFTMRWCJSA-N
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
アプリケーション
Quinidine sulfate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生物化学的／生理学的作用
クラスIA抗不整脈剤で、カリウムチャネルブロッカ-です。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
その他情報
Sales restrictions may apply.
関連製品
製品番号
詳細
価格
シグナルワード
Warning
危険有害性情報
危険有害性の分類
Acute Tox. 4 Oral
保管分類コード
11 - Combustible Solids
WGK
WGK 1
引火点(°F)
Not applicable
引火点(℃)
Not applicable
最新バージョンのいずれかを選択してください：
この製品を見ている人はこちらもチェック
Motoya Suzuki et al.
Xenobiotica; the fate of foreign compounds in biological systems, 44(11), 1039-1045 (2014-05-21)
1. This study was aimed to characterize gastrointestinal absorption of digoxin using wild-type (WT) and multidrug resistance protein 1a [mdr1a; P-glycoprotein (P-gp)] knockout (-/-) rats. 2. In WT rats, the area under the plasma concentration-time curve (AUC) of oral digoxin
Yuki Ogawa et al.
European journal of pediatrics, 174(4), 509-518 (2014-09-25)
This study aimed to determine the population pharmacokinetics of doxapram in low-birth-weight (LBW) infants. A total of 92 serum concentration measurements that were obtained from 34 Japanese neonates were analyzed using nonlinear mixed-effect modeling (NONMEM). Estimates generated by NONMEM indicated
Maria Addolorata Saracino et al.
Journal of pharmaceutical and biomedical analysis, 95, 61-67 (2014-03-19)
A rapid and reliable analytical method has been developed to quantify the melatonergic antidepressant agomelatine in three matrices, and namely saliva, plasma and dried blood spots. The method is based on the use of liquid chromatography with fluorimetric detection exploiting
Mikiko Tsukimoto et al.
Biopharmaceutics & drug disposition, 36(1), 15-33 (2014-09-30)
Aliskiren is a substrate for P-glycoprotein (P-gp) and is metabolized via cytochrome P450 3A4 (CYP3A4). The aim of the present study was to assess whether P-gp influenced the pharmacokinetics of aliskiren and also if drug-drug interactions (DDIs) mediated through P-gp
Laura Kervezee et al.
The AAPS journal, 16(5), 1029-1037 (2014-06-12)
Nearly all bodily processes exhibit circadian rhythmicity. As a consequence, the pharmacokinetic and pharmacodynamic properties of a drug may also vary with time of day. The objective of this study was to investigate diurnal variation in processes that regulate drug
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）